Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2224-2236
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2224
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2224
Table 2 Clinical studies of second-line monotherapeutic regimens
Ref. | Regimen | Sample size | RR1 | PFS/TTP (mo) | Med OS (mo) | 1 yr survival |
Jacobs et al[16], 2004 | Rubitecan | 198 | 11% | 1.9 | 3.5 | NR |
Burris et al[15], 2005 | Rubitecan | 58 | 5.2% | 2.0 | 3.1 | 9% |
Yi et al[78], 2009 | Irinotecan | 33 | 9% | 2.0 | 6.6 | NR |
Takahara et al[79], 2013 | Irinotecan | 56 | 3.6% | 2.9 | 5.3 | NR |
Ko et al[17], 2013 | Nanoliposomal irinotecan | 40 | 7.5% | 2.4 | 5.2 | 25% |
Oettle et al[18], 2000 | Paclitaxel | 18 | 5.6% | NR | 4.1 | NR |
Maeda et al[19], 2011 | Paclitaxel | 30 | 10% | NR | 6.7 | NR |
Cereda et al[20], 2008 | Docetaxel | 10 | 0% | 1.5 | 4.0 | 0% |
Hosein et al[22], 2013 | Nab-Paclitaxel | 19 | 5% | 1.7 | 7.3 | 37% |
Boeck et al[24], 2007 | Capecitabine | 39 | 0% | 2.3 | 7.6 | NR |
Bodoky et al[59], 2012 | Capecitabine | 38 | 7.9% | 2.2 | 5.0 | NR |
Morizane et al[25], 2009 | S-1 | 40 | 15% | 2.0 | 4.5 | 14% |
Todaka et al[26], 2010 | S-1 | 52 | 3.8% | 2.1 | 5.8 | 12% |
Mizuno et al[28], 2013 | S-1 | 67 | 6% | 1.9 | 5.9 | NR |
Ioka et al[27], 2013 | Best fluoropyrimidine2 | 40 | 10% | 3.8 | 7.5 | NR |
Fukahori et al[80], 2012 | Gemcitabine3 | 27 | 14% | 2.6 | 8.0 | NR |
Androulakis et al[81], 2005 | Oxaliplatin | 18 | 0% | NR | 3.5 | NR |
Boeck et al[82], 2007 | Pemetrexed | 52 | 3.8% | 1.6 | 4.7 | NR |
Ulrich-Pur et al[48], 2003 | Raltitrexed | 19 | 0% | 2.5 | 4.3 | 0% |
Kindler et al[83], 2008 | Arsenic trioxide | 13 | 0% | 1.6 | 3.8 | 0% |
- Citation: Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2224.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2224